Alliance Pharmaceutical Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: All Mtn Ski who wrote (508)	1/9/2001 1:02:37 PM
From: Cacaito	Read Replies (1) of 548

The patients did got Oxygent, there were more strokes in the treatment group (the control group is the one that did not got the drug), the "imbalance" means the oxygent patients had more strokes (apparently not statistically significant, but a trend enough to suspend the study and reevaluate strategies). Read: strokes were more in "the Oxygent treatment group BUT is in agreement with published data for patients undergoing cardiac bypass surgery, the control group frequency is remarkably low, causing a disparity in the proportion of AEs between the treatment and control patients." Please, notice in above paragraph I introduce a capital "BUT". This is the reason the stock went down from the $15 level to $7 and now that the public knows is down to $3. There is a chance indeed that oxygent cause the problem. That is why the market is reacting with a selloff. I am holding the stock cause of the Imavist approval is done and only they need to resolve the labels and the 2nd indication. Maybe, I will buy more, when more information is available.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next